Journals / Pharmata / 2023 / Cilt: 3 Sayı: 1

CISPLATIN NEFROTOXICITY AND TREATMENT APPROACHES

Journal
Pharmata
Pages
14–22
Publication Date
2023-01-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the molecular mechanisms of nephrotoxicity due to the use of cisplatin are described and the findings on current treatment approaches against cisplatin-induced kidney injury are summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is one of the most important health problem in the world.
📊
Key Findings & Data:Acute kidney injury (AKI) develops in 20-35% of patients after cisplatin administration.
💡
Conclusion & Impact:In this review, the molecular mechanisms of nephrotoxicity due to the use of cisplatin are described and the findings on current treatment approaches against cisplatin-induced kidney injury are summarized.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:cisplatin · nephrotoxicity · apoptosis

Abstract

Cancer is one of the most important health problem in the world. Cisplatin is an effective chemotherapeutic drug that is widely used in many cancer types such as lung, cervical, head and neck cancer, stomach cancer, testicular, ovarian, breast cancer. However, the clinical use of cisplatin is limited due to serious side effects and drug-induced resistance. Acute kidney injury (AKI) develops in 20-35% of patients after cisplatin administration. Long-term use of cisplatin results in tubular kidney damage, acute kidney failure, and chronic kidney disease in patients. Mechanisms of kidney injury induced by cisplatin use include proximal tubular damage, oxidative stress, ER stress, apoptosis, and inflammation in the kidneys. There is no completely effective drug or method for kidney damage due to cisplatin use. In vitro and in vivo studies have proven that many natural products and chemicals are effective against cisplatin-induced kidney damage in recent years. In this review, the molecular mechanisms of nephrotoxicity due to the use of cisplatin are described and the findings on current treatment approaches against cisplatin-induced kidney injury are summarized.

🔖

Cite This Article

KARAGÖL, N. (2023). CISPLATIN NEFROTOXICITY AND TREATMENT APPROACHES. Pharmata, Cilt: 3 Sayı: 1, 14–22. https://ajindex.com/articles/947923

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68: 394-424
  2. Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur. J. Cancer. 2021; 157: 308-47
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71: 209-49
  4. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73: 994-1007
  5. Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg. Chem. 2019; 88: 102925
  6. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 2014; 740: 364-78
  7. Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiology and oncology. 2019; 53(2): 148-58
  8. Zhang J, Ye Z-w, Tew KD, Townsend DM. Cisplatin chemotherapy and renal function. Adv. Cancer Res. 2021; 152: 305-27
  9. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007; 33: 9-23
  10. Hakiminia B, Goudarzi A, Moghaddas A. Has vitamin E any shreds of evidence in cisplatin‐induced toxicity. J. Biochem. Mol. Toxicol. 2019; 33: e22349
  11. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol. 2003; 14: 1-10
  12. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin‐induced nephrotoxicity. Clin. Pharmacol. Ther. 2009; 86: 396-402
  13. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009; 296: F505-F11
  14. Davoudi M, Jadidi Y, Moayedi K, Farrokhi V, Afrisham R. Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011–2022 review. J. Nanobiotechnology. 2022; 20: 1-33
  15. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010; 2: 2490-51